Earnings Call Summary | The Beauty Health(SKIN.US) Q1 2024 Earnings Conference
Earnings Call Summary | The Beauty Health(SKIN.US) Q1 2024 Earnings Conference
The following is a summary of the The Beauty Health Company (SKIN) Q1 2024 Earnings Call Transcript:
以下是美容健康公司（SKIN）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
The Beauty Health Company reported Q1 revenues of $81.4 million, a 5.7% year-over-year decline.
Gross margin was 59.4%, a decrease from the previous year's figure of 62.7%.
Global equipment revenue decreased by 21.1% due to tightening credit and prolonged lead-to-closure time.
A net loss of $700,000 was reported for Q1 2024.
Adjusted EBITDA was at $400,000, an improvement from Q1 2023's adjusted EBITDA loss of $500,000.
The company repurchased $192.3 million of convertible debt, with an inventory increase to $95.7 million, primarily for Syndeo 3.0 replacements.
For Q2, skin expects net sales of $96 million to $102 million and an adjusted EBITDA of $4 million to $7 million.
美容健康公司報告稱，第一季度收入爲8140萬美元，同比下降5.7％。
毛利率爲59.4％，較上一年的62.7％有所下降。
由於信貸緊縮和交貨時間延長，全球設備收入下降了21.1％。
據報道，2024年第一季度淨虧損70萬美元。
調整後的息稅折舊攤銷前利潤爲40萬美元，較2023年第一季度調整後的息稅折舊攤銷前利潤虧損50萬美元有所改善。
該公司回購了1.923億美元的可轉換債務，庫存增加至9,570萬美元，主要用於Syndeo 3.0的置換。
Skin預計第二季度的淨銷售額爲9,600萬至1.02億美元，調整後的息稅折舊攤銷前利潤爲400萬至700萬美元。
Business Progress:
業務進展：
The company's strategic priorities are sales excellence, operational excellence, and financial discipline.
Sheri Lewis was appointed as Chief Supply Chain and Operations officer.
Focus on global consumable sales and refining training programs for providers.
Future growth aims include major opportunities with Hydrafacial brand, segmentation of provider channels, and clinical studies of Hydrafacial treatments.
The Syndeo replacement program is ongoing, intending to replace approximately 1,000 more units.
The shift towards increased consumable sales has begun, with anticipations of improvement in new capital equipment sales throughout 2024.
該公司的戰略優先事項是卓越的銷售、卓越的運營和財務紀律。
謝里·劉易斯被任命爲首席供應鏈和運營官。
專注於全球消耗品銷售和完善供應商培訓計劃。
未來的增長目標包括Hydrafacial品牌的重大機遇、提供商渠道的細分以及Hydrafacial治療的臨床研究。
Syndeo的更換計劃正在進行中，打算再更換約1,000臺。
向增加消耗品銷售的轉變已經開始，預計2024年全年新資本設備的銷售將有所改善。
More details: The Beauty Health IR
更多詳情： 美容健康 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。